UL2-CHK: Neotract UroLift 2 Implant Cartridge Handle Kit

Sign in to add this product to your favorites!
| Price: | $999.00 per kit |
|---|---|
| In Stock: | 0 kits |
| Expiration: | In-Date |
We currently do not have this item in stock, but we can email you as soon as it is available.
Related Items
UL2-C $1,049.00 EACH Neotract UroLift 2 Implant Cartridge Exp: 04-2027 Units in stock: 5 | Order Qty |
UL2ATC-C-SD $999.99 EACH Neotract UroLift 2 ATC Implant Cartridge Exp: 08-2026 Units in stock: 3 | Order Qty |
UL2ATC-C-SD $1,999.99 per box of 2 Neotract UroLift 2 ATC Implant Cartridge Exp: 08-2026 Units in stock: 1 box of 2 | Order Qty |
Additional Details
Neotract UroLift 2 Implant Cartridge Handle Kit
Item # UL2-CHK
Includes Handle (UL2-H) + Cartridge (UL2-C)
AccessGUDID Info
- FDA Product Code: PEW
- FDA Product Code Name: Implantable transprostatic tissue retractor system
- GMDN Term Code: 58882
- GMDN Term Name: Prostatic retraction implant
- GMDN Term Description: A sterile implantable device intended to increase prostatic urethral patency, and thereby relieve lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH), by physically compressing the prostate gland by retraction. The implant is in the form of a two orthogonal tags (e.g., metal) held together by a suture (e.g., monofilament), and is introduced so that one tag is outside the prostatic capsule and the other is in the urethra, with the suture providing retraction. It is not intended to be explanted. The device is implanted using a dedicated, single-use, hand-held, pistol-like delivery device through the sheath of a rigid endoscope.
Manufacturer
Neotract, a Teleflex Company, is a medical device company specializing in minimally invasive solutions for the treatment of benign prostatic hyperplasia (BPH). Their flagship product, the UroLift System, is a minimally invasive procedure designed to relieve the symptoms of BPH by lifting and holding the enlarged prostate tissue out of the way of the urethra. The UroLift System is designed to be performed under local anesthesia and does not require cutting, heating, or removal of prostate tissue. Neotract's focus is on providing effective, low-risk treatments that offer patients a faster recovery and fewer side effects compared to traditional surgical options.
IN-DATE